BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murphy K, Murphy BT, Boyce S, Flynn L, Gilgunn S, O'Rourke CJ, Rooney C, Stöckmann H, Walsh AL, Finn S, O'Kennedy RJ, O'Leary J, Pennington SR, Perry AS, Rudd PM, Saldova R, Sheils O, Shields DC, Watson RW. Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer. Mol Oncol 2018;12:1513-25. [PMID: 29927052 DOI: 10.1002/1878-0261.12348] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Y, Sun H, Zheng J, Shao C. Analysis of RNA m6A methylation regulators and tumour immune cell infiltration characterization in prostate cancer. Artif Cells Nanomed Biotechnol 2021;49:407-35. [PMID: 33905280 DOI: 10.1080/21691401.2021.1912759] [Reference Citation Analysis]
2 Zhao Y, Sun H, Zheng J, Shao C, Zhang D. Identification of predictors based on drug targets highlights accurate treatment of goserelin in breast and prostate cancer. Cell Biosci 2021;11:5. [PMID: 33407865 DOI: 10.1186/s13578-020-00517-w] [Reference Citation Analysis]
3 Bertok T, Lorencova L, Hroncekova S, Gajdosova V, Jane E, Hires M, Kasak P, Kaman O, Sokol R, Bella V, Eckstein AA, Mosnacek J, Vikartovska A, Tkac J. Advanced impedimetric biosensor configuration and assay protocol for glycoprofiling of a prostate oncomarker using Au nanoshells with a magnetic core. Biosens Bioelectron 2019;131:24-9. [PMID: 30798249 DOI: 10.1016/j.bios.2019.01.052] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
4 Corbetta M, Chiereghin C, De Simone I, Soldà G, Zuradelli M, Giunta M, Lughezzani G, Buffi NM, Hurle R, Saita A, Casale P, Asselta R, Lazzeri M, Guazzoni G, Duga S. Post-Biopsy Cell-Free DNA From Blood: An Open Window on Primary Prostate Cancer Genetics and Biology. Front Oncol 2021;11:654140. [PMID: 34109115 DOI: 10.3389/fonc.2021.654140] [Reference Citation Analysis]
5 Tkac J, Gajdosova V, Hroncekova S, Bertok T, Hires M, Jane E, Lorencova L, Kasak P. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interface Focus 2019;9:20180077. [PMID: 30842876 DOI: 10.1098/rsfs.2018.0077] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
6 Bertok T, Jane E, Chrenekova N, Hroncekova S, Bertokova A, Hires M, Vikartovska A, Kubanikova P, Sokol R, Fillo J, Kasak P, Borsig L, Tkac J. Analysis of serum glycome by lectin microarrays for prostate cancer patients - a search for aberrant glycoforms. Glycoconj J 2020;37:703-11. [PMID: 33119808 DOI: 10.1007/s10719-020-09958-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 McNally CJ, Ruddock MW, Moore T, McKenna DJ. Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review. Cancer Manag Res 2020;12:5225-41. [PMID: 32669872 DOI: 10.2147/CMAR.S250829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
8 Liu D, Zhu J, Zhao T, Sharapov S, Tiys E, Wu L. Associations Between Genetically Predicted Plasma N-Glycans and Prostate Cancer Risk: Analysis of Over 140,000 European Descendants. Pharmgenomics Pers Med 2021;14:1211-20. [PMID: 34588798 DOI: 10.2147/PGPM.S319308] [Reference Citation Analysis]
9 Gilgunn S, Murphy K, Stöckmann H, Conroy PJ, Murphy TB, Watson RW, O'Kennedy RJ, Rudd PM, Saldova R. Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling. Int J Mol Sci 2020;21:E9233. [PMID: 33287410 DOI: 10.3390/ijms21239233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
10 Blsakova A, Kveton F, Kasak P, Tkac J. Antibodies against aberrant glycans as cancer biomarkers. Expert Rev Mol Diagn 2019;19:1057-68. [PMID: 31665948 DOI: 10.1080/14737159.2020.1687295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Momeni Z, Hassanzadeh E, Saniee Abadeh M, Bellazzi R. A survey on single and multi omics data mining methods in cancer data classification. Journal of Biomedical Informatics 2020;107:103466. [DOI: 10.1016/j.jbi.2020.103466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Jones AL, Dhanapala L, Baldo TA, Sharafeldin M, Krause CE, Shen M, Moghaddam S, Faria RC, Dey DK, Watson RW, Andrawis R, Lee NH, Rusling JF. Prostate Cancer Diagnosis in the Clinic Using an 8-Protein Biomarker Panel. Anal Chem 2021;93:1059-67. [PMID: 33289381 DOI: 10.1021/acs.analchem.0c04034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Dong M, Lih TM, Höti N, Chen SY, Ponce S, Partin A, Zhang H. Development of Parallel Reaction Monitoring Assays for the Detection of Aggressive Prostate Cancer Using Urinary Glycoproteins. J Proteome Res 2021;20:3590-9. [PMID: 34106707 DOI: 10.1021/acs.jproteome.1c00162] [Reference Citation Analysis]
14 Moghaddam S, Jalali A, O'Neill A, Murphy L, Gorman L, Reilly AM, Heffernan Á, Lynch T, Power R, O'Malley KJ, Taskèn KA, Berge V, Solhaug VA, Klocker H, Murphy TB, Watson RW. Integrating Serum Biomarkers into Prediction Models for Biochemical Recurrence Following Radical Prostatectomy. Cancers (Basel) 2021;13:4162. [PMID: 34439316 DOI: 10.3390/cancers13164162] [Reference Citation Analysis]
15 Bertok T, Jane E, Bertokova A, Lorencova L, Zvara P, Smolkova B, Kucera R, Klocker H, Tkac J. Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies. Cancers (Basel) 2020;12:E2988. [PMID: 33076457 DOI: 10.3390/cancers12102988] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Capobianco E, Dominietto M. From Medical Imaging to Radiomics: Role of Data Science for Advancing Precision Health. J Pers Med 2020;10:E15. [PMID: 32121633 DOI: 10.3390/jpm10010015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
17 Hires M, Jane E, Mego M, Chovanec M, Kasak P, Tkac J. Glycan Analysis as Biomarkers for Testicular Cancer. Diagnostics (Basel) 2019;9:E156. [PMID: 31652641 DOI: 10.3390/diagnostics9040156] [Reference Citation Analysis]
18 Yuan W, Liu B, Sanda M, Wei R, Benicky J, Novakova Z, Barinka C, Goldman R. Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue. Prostate 2022;82:132-44. [PMID: 34662441 DOI: 10.1002/pros.24254] [Reference Citation Analysis]
19 Kunej T. Rise of Systems Glycobiology and Personalized Glycomedicine: Why and How to Integrate Glycomics with Multiomics Science? OMICS. 2019;23:615-622. [PMID: 31651212 DOI: 10.1089/omi.2019.0149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
20 Scott E, Munkley J. Glycans as Biomarkers in Prostate Cancer. Int J Mol Sci 2019;20:E1389. [PMID: 30893936 DOI: 10.3390/ijms20061389] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
21 Bienes KM, Tautau FAP, Mitani A, Kinoshita T, Nakakita SI, Higuchi Y, Takegawa K. Characterization of novel endo-β-N-acetylglucosaminidase from Bacteroides nordii that hydrolyzes multi-branched complex type N-glycans. J Biosci Bioeng 2022:S1389-1723(22)00089-5. [PMID: 35484013 DOI: 10.1016/j.jbiosc.2022.03.011] [Reference Citation Analysis]
22 Zhang E, Hou X, Hou B, Zhang M, Song Y. A risk prediction model of DNA methylation improves prognosis evaluation and indicates gene targets in prostate cancer. Epigenomics 2020;12:333-52. [PMID: 32027524 DOI: 10.2217/epi-2019-0349] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
23 Wang X, Zhong Z, Wang W. COVID-19 and Preparing Planetary Health for Future Ecological Crises: Hopes from Glycomics for Vaccine Innovation. OMICS 2021;25:234-41. [PMID: 33794117 DOI: 10.1089/omi.2021.0011] [Reference Citation Analysis]
24 Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG. Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. Eur Urol Open Sci 2020;21:51-60. [PMID: 34337468 DOI: 10.1016/j.euros.2020.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kałuża A, Szczykutowicz J, Ferens-Sieczkowska M. Glycosylation: Rising Potential for Prostate Cancer Evaluation. Cancers (Basel) 2021;13:3726. [PMID: 34359624 DOI: 10.3390/cancers13153726] [Reference Citation Analysis]
26 Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol 2019;15:346-66. [PMID: 30858582 DOI: 10.1038/s41581-019-0129-4] [Cited by in Crossref: 287] [Cited by in F6Publishing: 263] [Article Influence: 143.5] [Reference Citation Analysis]
27 Delacourt AT, Mehta AS. Liver Cancer (Current Therapies). Reference Module in Biomedical Sciences. Elsevier; 2021. [DOI: 10.1016/b978-0-12-820472-6.00007-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Jeyapala R, Kamdar S, Olkhov-mitsel E, Zlotta A, Fleshner N, Visakorpi T, van der Kwast T, Bapat B. Combining CAPRA-S with tumor IDC/C features improves the prognostication of biochemical recurrence in prostate cancer patients. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.01.003] [Reference Citation Analysis]
29 Zhang E, Zhang M, Shi C, Sun L, Shan L, Zhang H, Song Y. An overview of advances in multi-omics analysis in prostate cancer. Life Sci 2020;260:118376. [PMID: 32898525 DOI: 10.1016/j.lfs.2020.118376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Tkac J, Bertok T, Hires M, Jane E, Lorencova L, Kasak P. Glycomics of prostate cancer: updates. Expert Rev Proteomics 2019;16:65-76. [PMID: 30451032 DOI: 10.1080/14789450.2019.1549993] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
31 Fitzgerald J, Higgins D, Mazo Vargas C, Watson W, Mooney C, Rahman A, Aspell N, Connolly A, Aura Gonzalez C, Gallagher W. Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer. J Clin Pathol 2021;74:429-34. [PMID: 34117103 DOI: 10.1136/jclinpath-2020-207351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ramberg H, Richardsen E, de Souza GA, Rakaee M, Stensland ME, Braadland PR, Nygård S, Ögren O, Guldvik IJ, Berge V, Svindland A, Taskén KA, Andersen S. Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer. Carcinogenesis 2021;42:685-93. [PMID: 33609362 DOI: 10.1093/carcin/bgab015] [Reference Citation Analysis]
33 Tokareva AO, Chagovets VV, Starodubtseva NL, Nazarova NM, Nekrasova ME, Kononikhin AS, Frankevich VE, Nikolaev EN, Sukhikh GT. Feature selection for OPLS discriminant analysis of cancer tissue lipidomics data. J Mass Spectrom 2020;55:e4457. [PMID: 31661719 DOI: 10.1002/jms.4457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]